This is consistent with results indicating that enhanced FGFR signaling predisposed pancreatic cancer cells to the killing effect of dovitinib, a potent FGFR inhibitor, in preclinical models [8], thus indicating that the pharmacological or molecular targeting of FGFR1 in patients with PDAC has therapeutic potential. Here, FGFR1 is linked to pancreatic neoplasm.